CoChat
Sign Up
Cited by 172Treatment of Major DepressionMental Health Treatment and AccessAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants

Open access
Hansen, Richard, Gaynes, Bradley, Thieda, Patricia, Gartlehner, Gerald, Deveaugh-Geiss, Angela, Krebs, Erin, Lohr, Kathleen·2008·Psychiatric Services
DOI 10.1176/ps.2008.59.10.1121PMC PMC2840386
Open this paper in CoChat — free account

Abstract

OBJECTIVE: This meta-analysis reviewed data on the efficacy and effectiveness of second-generation antidepressants for preventing major depression relapse and recurrence during continuation and maintenance phases of treatment, respectively. METHODS: MEDLINE, EMBASE, and PsycINFO, the Cochrane Library, and International Pharmaceutical Abstracts were searched for the period of January 1980 through April 2007 for reviews, randomized controlled trials, meta-analyses, and observational studies on the topic. Two persons independently reviewed abstracts and full-text articles using a structured data abstraction form to ensure consistency in appraisal and data extraction. RESULTS: Four comparative trials and 23 placebo-controlled trials that addressed relapse or recurrence prevention were included. Results of comparative trials have not demonstrated statistically significant differences between duloxetine and paroxetine, fluoxetine and sertraline, fluvoxamine and sertraline, and trazodone and venlafaxine. Pooled data for the class of second-generation antidepressants compared with placebo suggested a relatively large effect size that persists over time. For preventing both relapse and recurrence, the number of patients needed to treat is five (95% confidence interval of 4 to 6). Differences in the length of open-label treatment before randomization, drug type, and trial duration did not affect pooled estimates of relapse rates. Across all trials, 7% of patients randomly assigned to receive active treatment and 5% of patients randomly assigned to receive a placebo discontinued treatment because of adverse events. CONCLUSIONS: This review demonstrates the overall benefits of continuation- and maintenance-phase treatment of major depression with second-generation antidepressants and emphasizes the need for additional studies of comparative differences among drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/ps.2008.59.10.1121

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. Gaynes is with the Department of Psychiatry, Ms., Thieda is with Cecil G
  2. Austria Dr., Krebs is with the Department of Medicine
  3. Dr, Hansen at the School of Pharmacy
  4. not reported
  5. Montgomery-Asberg Depression Rating Scale (possible scores range from 0 to 60, with higher scores indicating greater severity of symptoms)
  6. not applicable
  7. Clinical Global Impression of Severity (possible scores range from 1 to 7, with lower scores indicating normalcy or mild illness and higher scores indicating more severe illness)
  8. with higher scores indicating greater severity of symptoms) d SR, sustained release e Active treatment versus placebo f Not included in meta-analysis
  9. Depression Guideline Panel, 1993, Md, US Department of Health and Human Services, Public Health Service
  10. Loonen AJ, 1991, Scientific Edition, 13, 167
  11. Undertaking Systematic Reviews, 2001, CRD's Guidance for Those Carrying Out or Commissioning Reviews. CRD report no 4
  12. Egger M, 2001, Smith GD
  13. Gartlehner G, 2006, Md
  14. Glenny AM, 2005, Indirect comparisons of competing interventions. Health Technology Assessment 9(special issue):1-134

Cited by

Sorted by citations

See all 172

Related

See all

Metadata

Authors
Hansen, R., Gaynes, B., Thieda, P., Gartlehner, G., Deveaugh-Geiss, A., Krebs, E., & Lohr, K.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • RTI International (US)
Corresponding author
Hansen, Richard
ORCID
Venue
Psychiatric Services
Publisher
American Psychiatric Association Publishing
Published
2008-10
Volume
59
Issue
10
Pages
1121-1130
ISSN
  • 0022-1597 (ISSN-L)
  • 1075-2730
  • 1557-9700
DOI
10.1176/ps.2008.59.10.1121
PMC
PMC2840386
OpenAlex
W4236472310
Cited by
172
References
45
Citations by year
2026: 5 · 2025: 4 · 2024: 7 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 7 · 2017: 16 · 2016: 5 · 2015: 32 · 2014: 7 · 2013: 6 · 2012: 13
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • Psychiatric Services (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
Funders
  • Pfizer
  • GlaxoSmithKline
  • RTI International
  • Shire
  • National Institutes of Health
  • Agency for Healthcare Research and Quality (290-02-0016)
  • University of North Carolina at Chapel Hill
  • National Institute of Mental Health
  • National Center for Research Resources (K12RR023248)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
major depressive disorder, depression relapse, depression recurrence, second-generation antidepressants, continuation treatment, maintenance therapy, duloxetine, paroxetine, fluoxetine, sertraline, fluvoxamine, trazodone, venlafaxine, antidepressant efficacy, adverse events
MeSH terms
Adult, Aged, Aged, 80 and over, Depressive Disorder, Major, Major Depressive Disorder, Humans, Middle Aged, Recurrence, Randomized Controlled Trials as Topic, Outcome Assessment, Health Care, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review